Decreased B4GALT1 promotes hepatocellular carcinoma cell invasiveness by regulating the laminin-integrin pathway.
Journal
Oncogenesis
ISSN: 2157-9024
Titre abrégé: Oncogenesis
Pays: United States
ID NLM: 101580004
Informations de publication
Date de publication:
31 Oct 2023
31 Oct 2023
Historique:
received:
17
01
2023
accepted:
11
10
2023
revised:
26
09
2023
medline:
1
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
epublish
Résumé
Beta1,4-galactosyltransferases (B4GALTs) play a crucial role in several diseases, including cancer. B4GALT1 is highly expressed in the liver, and patients with mutations in B4GALT1 exhibit hepatopathy. However, the role of B4GALT1 in liver cancer remains unclear. Here, we found that B4GALT1 was significantly downregulated in hepatocellular carcinoma (HCC) tissue compared with the adjacent liver tissue, and low B4GALT1 expression was associated with vascular invasion and poor overall survival in patients with HCC. Additionally, silencing or loss of B4GALT1 enhanced HCC cell migration and invasion in vitro and promoted lung metastasis of HCC in NOD/SCID mice. Moreover, B4GALT1 knockdown or knockout increased cell adhesion to laminin, whereas B4GALT1 overexpression decreased the adhesion. Through a mass spectrometry-based approach and Griffonia simplicifolia lectin II (GSL-II) pull-down assays, we identified integrins α6 and β1 as the main protein substrates of B4GALT1 and their N-glycans were modified by B4GALT1. Further, the increased cell migration and invasion induced by B4GALT1 knockdown or knockout were significantly reversed using a blocking antibody against integrin α6 or integrin β1. These results suggest that B4GALT1 downregulation alters N-glycosylation and enhances the laminin-binding activity of integrin α6 and integrin β1 to promote invasiveness of HCC cells. Our findings provide novel insights into the role of B4GALT1 in HCC metastasis and highlight targeting the laminin-integrin axis as a potential therapeutic strategy for HCC with low B4GALT1 expression.
Identifiants
pubmed: 37907465
doi: 10.1038/s41389-023-00494-y
pii: 10.1038/s41389-023-00494-y
pmc: PMC10618527
doi:
Types de publication
Journal Article
Langues
eng
Pagination
49Informations de copyright
© 2023. The Author(s).
Références
Eur J Surg Oncol. 2022 Mar;48(3):492-499
pubmed: 34602315
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820980104
pubmed: 33287670
Clin Exp Metastasis. 2022 Apr;39(2):291-301
pubmed: 34822024
Hepatol Commun. 2022 Apr;6(4):652-664
pubmed: 34738743
Gastric Cancer. 2022 Jan;25(1):107-123
pubmed: 34554347
Nat Rev Immunol. 2018 Mar;18(3):204-211
pubmed: 29398707
Hepatol Commun. 2022 Jul;6(7):1786-1802
pubmed: 35238496
Nat Rev Drug Discov. 2022 Jan;21(1):60-78
pubmed: 34535788
Proc Natl Acad Sci U S A. 2012 Jun 19;109(25):9893-8
pubmed: 22566642
Cell Prolif. 2020 Jul;53(7):e12836
pubmed: 32537856
J Hepatol. 2008 Dec;49(6):1029-37
pubmed: 18929424
Exp Ther Med. 2012 Mar;3(3):415-422
pubmed: 22969905
Nat Rev Clin Oncol. 2018 Oct;15(10):599-616
pubmed: 30061739
Cell Physiol Biochem. 2018;48(1):397
pubmed: 30071532
Int J Mol Sci. 2020 Jan 09;21(2):
pubmed: 31936666
J Biotechnol. 2018 Sep 20;282:101-110
pubmed: 30017654
EMBO Rep. 2006 Jun;7(6):599-604
pubmed: 16741504
Glycoconj J. 2004;21(1-2):9-15
pubmed: 15467392
J Biol Chem. 2009 May 1;284(18):12207-16
pubmed: 19261610
N Engl J Med. 2019 Apr 11;380(15):1450-1462
pubmed: 30970190
Hepatobiliary Pancreat Dis Int. 2004 Nov;3(4):548-51
pubmed: 15567743
Eur J Med Res. 2013 Dec 04;18:52
pubmed: 24304619
Gene Expr Patterns. 2006 Apr;6(4):376-82
pubmed: 16412699
Adv Exp Med Biol. 2010;674:107-23
pubmed: 20549944
J Pediatr. 2011 Dec;159(6):1041-3.e2
pubmed: 21920538
Mol Biol Cell. 2002 Jun;13(6):1929-39
pubmed: 12058060
Nat Commun. 2020 Jan 17;11(1):356
pubmed: 31953383
Nat Rev Cancer. 2018 Sep;18(9):533-548
pubmed: 30002479
Front Genet. 2022 Dec 09;13:882004
pubmed: 36568388
J Gastroenterol Hepatol. 2018 Feb;33(2):347-354
pubmed: 28589639
Cancer Res. 2010 Dec 15;70(24):10202-12
pubmed: 21159642
Mol Biol Rep. 2011 Jun;38(5):3271-6
pubmed: 21359644
Gut. 1998 Dec;43(6):837-42
pubmed: 9824613
BMC Cancer. 2018 May 24;18(1):590
pubmed: 29793447
Cell Biosci. 2020 Oct 31;10(1):127
pubmed: 33292459
Expert Opin Ther Targets. 2011 Apr;15(4):421-37
pubmed: 21332366
J Clin Med. 2019 Nov 09;8(11):
pubmed: 31717588
J Hepatol. 2022 Mar;76(3):681-693
pubmed: 34801630
Trends Cancer. 2018 Aug;4(8):537-552
pubmed: 30064662
Curr Drug Targets. 2008 Apr;9(4):292-309
pubmed: 18393823
Mol Cancer. 2007 May 09;6:32
pubmed: 17488527
Oncotarget. 2016 May 31;7(22):32723-30
pubmed: 27092876
Nat Rev Gastroenterol Hepatol. 2014 Jul;11(7):392
pubmed: 24890282
Hum Pathol. 1997 Oct;28(10):1131-8
pubmed: 9343319
Nat Rev Cancer. 2015 Sep;15(9):540-55
pubmed: 26289314
Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):472-7
pubmed: 9435216
Hepatology. 2018 Jan;67(1):422-435
pubmed: 28881497
FEBS Open Bio. 2020 Dec;10(12):2750-2760
pubmed: 33098235
Cancer Biomark. 2018;23(1):135-144
pubmed: 30010110
Mol Biol Rep. 2010 Mar;37(3):1665-70
pubmed: 19768654
Sci Rep. 2017 Jul 5;7(1):4656
pubmed: 28680094
Cancer Lett. 2021 Mar 1;500:228-243
pubmed: 33309857